In terms of study limitations, the STZ model chosen reflects insulin deficient hyperglycemia while the majority of patients potentially in need of cell therapy are type 2 diabetics with both hyperglycemia and insulin resistance. The gene discussed is INS; the disease is Hyperglycemia.